A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

Organon

Status and phase: Completed; Phase 4

Conditions: Acute Gout

Treatments: Drug: Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days; Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days

Study type: Interventional

Funder types: Industry

Identifiers

NCT00142558

0663-081

2005_062

MK0663-081

Details and patient eligibility

About

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Enrollment: 180 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Males or females at least 18 years of age who have acute gout.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind